Wegovy maker Novo's profit warning triggers $70 billion share rout
ADVERTISEMENT Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started.
Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8% and 14%, from between 13% and 21% previously. Its shares plunged nearly 30% before paring some losses to trade down over 20% by mid-afternoon. The shares are now down 44% this year.
"The magnitude of the guidance cut is a shocker," Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than "compounded" copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. U.S. law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations.
ADVERTISEMENT The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the U.S., both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
ADVERTISEMENT At its peak in June 2024, Novo was worth as much as $615 billion, but its shares have plunged on investor concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market. "The stock has gone from being a market darling to one of its biggest letdowns," said Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, which has a small Novo stake. "The biggest concern is the illegal channel siphoning away market share - something that's hard to quantify. Rebuilding trust will take time."
ADVERTISEMENT
Novo Nordisk share price in Danish krone Doustdar, an Iranian-born, Austrian national, who grew up in the United States, joined Novo in 1992 and will take on the new role on August 7.
ADVERTISEMENT He currently serves as vice president for international operations, a role he took after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. "We need to increase the sense of urgency and execute differently," Doustdar told investors and analysts on a call. "The fact that my announcement comes right after the guidance update, just makes the mandate ahead even more clear." Some analysts and investors had argued that Novo should select an American, or a person with extensive experience working in the United States as its next CEO. Novo has lost its first-mover advantage in the United States this year to U.S. rival Eli Lilly. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the United States, the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. In May, Novo said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22. "Unfortunately, our latest market research indicates that has not happened," Chief Financial Officer Karsten Munk Knudsen said on a call with analysts on Tuesday. One million or more U.S. patients are still using compounded GLP-1s, he said.
Novo has stepped up its dialogue with the U.S. FDA to limit unlawful compounding of its drugs, the head of U.S. operations David Moore added on the call. "Compounding continues to be an issue that we have to address," Moore said.
(You can now subscribe to our ETMarkets WhatsApp channel)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
8 minutes ago
- Indian Express
Don't give China pass, burn relationship with ‘strong ally' India: Nikki Haley
The US should not burn its relationship with a 'strong ally like India' and give a pass to China, Indian-American Republican leader Nikki Haley said on Tuesday, amid President Donald Trump's attacks against New Delhi over tariffs and purchases of Russian oil. 'India should not be buying oil from Russia. But China, an adversary and the number one buyer of Russian and Iranian oil, got a 90-day tariff pause,' Haley said in a post on X. 'Don't give China a pass and burn a relationship with a strong ally like India,' she said. Haley, the former Governor of South Carolina, was the US Ambassador to the United Nations under Trump's first presidential term, becoming the first Indian-American to be appointed to a cabinet-level post in the US administration. India should not be buying oil from Russia. But China, an adversary and the number one buyer of Russian and Iranian oil, got a 90-day tariff pause. Don't give China a pass and burn a relationship with a strong ally like India. — Nikki Haley (@NikkiHaley) August 5, 2025 In 2013, she officially announced her candidacy for the 2024 presidential election and withdrew from the race in March last year. Her comments came hours after Trump said India has not been a 'good trading partner' and announced he will raise tariffs on India 'very substantially over the next 24 hours' because New Delhi is buying Russian oil and 'fueling' the 'war machine'. India on Monday mounted an unusually sharp counterattack on the US and the European Union for their 'unjustified and unreasonable' targeting of New Delhi for its procurement of Russian crude oil. New Delhi's response came after Trump asserted that Washington will substantially raise tariffs on goods from India over its energy ties with Russia. Meanwhile, Trump, in an interview with CNBC responded to a question on China and its leader, Xi Jinping, and said, 'We have a very good relationship'. Trump added that he might have a meeting with the Chinese President 'before the end of the year, most likely, if we make a deal.' He said he won't have a meeting if a deal doesn't materialise. 'But we're getting very close to a deal. We're getting along with China very well.' Trump added that China is 'very reliant' on the US. 'My relationship with them is very good. I think we'll make a good deal. It's not imperative, but I think we're going to make a good deal.' He added that he has had a 'great relationship' with President Xi. 'We respect him a lot. They respect us a lot.'
Hindustan Times
an hour ago
- Hindustan Times
Kelley Mack cause of death: What is glioma of the central nervous system? All on Chicago Med star's health issues
Kelley Mack, actor famous for her roles in 'The Walking Dead', '9-1-1' and 'Chicago Med', died last week, her family confirmed on Tuesday. She was 33 years old. It is reported that she passed away in her hometown of Cincinnati after a battle with glioma of the central nervous system. Kelley Mack died of glioma of the central nervous system at 33(X) Mack graduated from Hinsdale Central High School in 2010 and went on to earn a bachelor's degree in cinematography from Chapman University's Dodge College of Film in 2014. Her interest in performing began after receiving a mini video camera as a birthday gift, which led to appearances in commercials as a child actor. She later won an acting award from NYU's Tisch School of the Arts for her debut performance in The Elephant Garden, a film that earned the Student Visionary Award at the 2008 Tribeca Film Festival. She was best known for her television roles, including Addy in Season 9 of The Walking Dead, Penelope Jacobs in Season 8 of Chicago Med, and appearances on FOX's 9-1-1. Her film credits include Alice in Broadcast Signal Intrusion, Wilda in Delicate Arch, and Ricky in the upcoming Universal. Beyond acting, Kelly Mack was also a screenwriter, collaborating with her mother, Kristen Klebenow, on multiple feature-length scripts. Among their projects was On The Black, a 1950s-era college baseball story inspired by her maternal grandparents' time at Ohio University. She is survived by her parents, Kristen and Lindsay Klebenow; sister Kathryn; brother Parker; and grandparents Lois and Larry Klebenow. What is glioma of the central nervous system? According to the Cleveland Clinic, a glioma 'is a tumor that forms when glial cells grow out of control. Normally, these cells support nerves and help your central nervous system work. Gliomas usually grow in the brain, but can also form in the spinal cord'. 'Gliomas are malignant (cancerous), but some can be very slow growing. They're primary brain tumors, meaning they originate in the brain tissue,' the website further states.
India.com
an hour ago
- India.com
‘I Never Said A Percentage': Trump Backtracks On Russian Oil Tariff Threat — What It Means For India, China And Who's Really In The Crosshairs
Washington: What began as a routine press briefing on the 2028 Los Angeles Olympics quickly turned into a window into Donald Trump's evolving global agenda. Fielding an unexpected question, the U.S. president pivoted, hinting at fresh tariffs on countries buying Russian oil. The off-the-cuff remark, though brief, sent ripples through foreign capitals, exposing a potentially dramatic shift in U.S. economic pressure tactics that could hit allies like India, even as China avoids similar scrutiny. 'I never said a percentage. But we will be doing quite a bit of that. We will see what happens over the next fairly short period of time. We have a meeting with Russia tomorrow. We are going to see what happens,' Trump clarified when asked about plans for a 100% tariff. This statement followed earlier his remarks, suggesting he could raise tariffs on Indian imports 'very substantially' within 24 hours. He explained that the reason was India's continued energy trade with Russia. 'They are fueling the war machine, and if they are going to do that, then I am not going to be happy,' Trump told CNBC in an interview, as reported by Reuters. He also flagged India's existing tariff structure as a sticking point in bilateral trade. Trump first posted the warning on his social media platform Truth Social. There, he said, 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits. They don't care how many people in Ukraine are being killed by the Russian War Machine. Because of this, I will be substantially raising the Tariff paid by India to the USA. Thank you for your attention to this matter!!!' Former U.S, Ambassador to the United Nations, Nikki Haley, also weighed in on the matter. In a post on X (formerly Twitter), she called attention to how the Trump administration has treated China during this time. She pointed out that China, which she described as an adversary and the 'number one buyer of Russian and Iranian oil', had been granted a 90-day tariff pause. 'India should not be buying oil from Russia. But China, an adversary and the number one buyer of Russian and Iranian oil, got a 90-day tariff pause. Don't give China a pass and burn a relationship with a strong ally like India,' she posted. Haley previously competed in the Republican primaries but was the last of Trump's major rivals to exit the race. While Trump continues to signal tariff hikes, Haley's statement serves as a reminder of the broader geopolitical implications. The conversation around oil imports, strategic alliances and tariff policy now includes strong voices from within the U.S. political establishment. The days ahead may bring new policy decisions and further clarification on tariffs, as the White House prepares for its meeting with Russia.
